September 27, 2016
Colleen Lawton, MD, FASTRO
The addition of external beam therapy to brachytherapy did not significantly extend PFS among men with intermediate-risk prostate cancer, according to the initial report of a phase 3 study presented at the ASTRO Annual Meeting.
Thus, radiation treatment with brachytherapy alone may provide adequate cancer control for this population, resulting in fewer long-term adverse events, results showed.
Meeting News Coverage
September 26, 2016
Black cancer survivors appeared more likely than white survivors to face lasting debt and limit their medical care due to cost concerns, according to study results…
HemOnc Today, September 25, 2016
Derek Raghavan, MD, PhD
Rusthoven and colleagues recently reported a post-hoc analysis of 6,382 men with newly diagnosed metastatic prostate cancer treated with androgen deprivation therapy, of…
September 23, 2016
National Prostate Cancer Awareness Month, observed in September, is intended to educate men about disease risk factors, screening options and other matters related to…